context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 575.0 | monetaryItemType | text: <entity> 575.0 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectiv... | us-gaap:LongTermDebt |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amo... | text | 99.6 | percentItemType | text: <entity> 99.6 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectivel... | us-gaap:DebtInstrumentRedemptionPricePercentage |
On September 16, 2024, after completing the tender offer, the Company irrevocably deposited with the trustee under the indenture governing the 2025 Senior Notes, U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest and the remaining $ 318.0 million aggregate principal a... | text | 318.0 | monetaryItemType | text: <entity> 318.0 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, after completing the tender offer, the Company irrevocably deposited with the trustee under the indenture governing the 2025 Senior Notes, U.S. government obligations in an amount sufficient to fund the payment... | us-gaap:EarlyRepaymentOfSeniorDebt |
On September 16, 2024, after completing the tender offer, the Company irrevocably deposited with the trustee under the indenture governing the 2025 Senior Notes, U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest and the remaining $ 318.0 million aggregate principal a... | text | 291.9 | monetaryItemType | text: <entity> 291.9 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, after completing the tender offer, the Company irrevocably deposited with the trustee under the indenture governing the 2025 Senior Notes, U.S. government obligations in an amount sufficient to fund the payment... | us-gaap:EarlyRepaymentOfSeniorDebt |
In July 2021, Viatris entered into the ¥ 40 billion YEN Term Loan Facility with various syndicates of banks. The YEN Term Loan Facility will mature in July 2026. On September 27, 2024, Viatris entered into a $ 3.5 billion amended and restated revolving credit agreement (the “2024 Revolving Facility”) with a syndicate o... | text | 40 | monetaryItemType | text: <entity> 40 </entity> <entity type> monetaryItemType </entity type> <context> In July 2021, Viatris entered into the ¥ 40 billion YEN Term Loan Facility with various syndicates of banks. The YEN Term Loan Facility will mature in July 2026. On September 27, 2024, Viatris entered into a $ 3.5 billion amended and re... | us-gaap:DebtInstrumentFaceAmount |
In July 2021, Viatris entered into the ¥ 40 billion YEN Term Loan Facility with various syndicates of banks. The YEN Term Loan Facility will mature in July 2026. On September 27, 2024, Viatris entered into a $ 3.5 billion amended and restated revolving credit agreement (the “2024 Revolving Facility”) with a syndicate o... | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> In July 2021, Viatris entered into the ¥ 40 billion YEN Term Loan Facility with various syndicates of banks. The YEN Term Loan Facility will mature in July 2026. On September 27, 2024, Viatris entered into a $ 3.5 billion amended and r... | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
The YEN Term Loan Facility and the 2024 Revolving Facility contain customary affirmative covenants for facilities of this type, including among others, covenants pertaining to the delivery of financial statements, notices of default and certain material events, maintenance of corporate existence and rights, property, a... | text | 1.65 | monetaryItemType | text: <entity> 1.65 </entity> <entity type> monetaryItemType </entity type> <context> The YEN Term Loan Facility and the 2024 Revolving Facility contain customary affirmative covenants for facilities of this type, including among others, covenants pertaining to the delivery of financial statements, notices of default a... | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
At December 31, 2024 and 2023, the aggregate fair value of the Company’s outstanding notes was approximately $ 11.53 billion and $ 15.25 billion, respectively. The fair values of the outstanding notes were valued at quoted market prices from broker or dealer quotations and were classified as Level 2 in the fair value h... | text | 11.53 | monetaryItemType | text: <entity> 11.53 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, the aggregate fair value of the Company’s outstanding notes was approximately $ 11.53 billion and $ 15.25 billion, respectively. The fair values of the outstanding notes were valued at quoted market pri... | us-gaap:DebtInstrumentFairValue |
At December 31, 2024 and 2023, the aggregate fair value of the Company’s outstanding notes was approximately $ 11.53 billion and $ 15.25 billion, respectively. The fair values of the outstanding notes were valued at quoted market prices from broker or dealer quotations and were classified as Level 2 in the fair value h... | text | 15.25 | monetaryItemType | text: <entity> 15.25 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, the aggregate fair value of the Company’s outstanding notes was approximately $ 11.53 billion and $ 15.25 billion, respectively. The fair values of the outstanding notes were valued at quoted market pri... | us-gaap:DebtInstrumentFairValue |
For those foreign subsidiaries whose investments are permanent in duration, income and foreign withholding taxes have not been provided on the unremitted earnings of those subsidiaries. This amount may become taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. The amoun... | text | 1.11 | monetaryItemType | text: <entity> 1.11 </entity> <entity type> monetaryItemType </entity type> <context> For those foreign subsidiaries whose investments are permanent in duration, income and foreign withholding taxes have not been provided on the unremitted earnings of those subsidiaries. This amount may become taxable upon a repatriati... | us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries |
During the year ended December 31, 2024, as a result of legislation changes surrounding Pillar Two Global Anti-Base Erosion Rules (“Pillar Two Rules”), the Company recognized $ 734.6 million of previously unrecorded Luxembourg net operating losses which are offset by a corresponding valuation allowance. During the year... | text | 734.6 | monetaryItemType | text: <entity> 734.6 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, as a result of legislation changes surrounding Pillar Two Global Anti-Base Erosion Rules (“Pillar Two Rules”), the Company recognized $ 734.6 million of previously unrecorded Luxembourg net op... | us-gaap:DeferredTaxAssetsOperatingLossCarryforwards |
A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2024, a valuation allowance has been applied to certain deferred tax assets in the amount of $ 1.23 billion. | text | 1.23 | monetaryItemType | text: <entity> 1.23 </entity> <entity type> monetaryItemType </entity type> <context> A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2024, a valuation allowance has been applied to certain deferred tax assets in... | us-gaap:DeferredTaxAssetsValuationAllowance |
U.S. federal net operating loss carryforwards of $ 247.6 million, which were recorded in connection with the Oyster Point acquisition. While the utilization of these carryforwards is subject to Section 382 of the Code, the Company does not anticipate that this limitation will impair our ability to utilize the carryover... | text | 247.6 | monetaryItemType | text: <entity> 247.6 </entity> <entity type> monetaryItemType </entity type> <context> U.S. federal net operating loss carryforwards of $ 247.6 million, which were recorded in connection with the Oyster Point acquisition. While the utilization of these carryforwards is subject to Section 382 of the Code, the Company do... | us-gaap:OperatingLossCarryforwards |
U.S. state income tax loss carryforwards of approximately $ 3.40 billion, which are largely offset by a valuation allowance. | text | 3.40 | monetaryItemType | text: <entity> 3.40 </entity> <entity type> monetaryItemType </entity type> <context> U.S. state income tax loss carryforwards of approximately $ 3.40 billion, which are largely offset by a valuation allowance. </context> | us-gaap:OperatingLossCarryforwards |
Non-U.S. net operating loss carryforwards of approximately $ 4.47 billion, of which $ 2.34 billion can be carried forward indefinitely, with the remaining $ 2.13 billion expiring in years 2025 through 2044. | text | 4.47 | monetaryItemType | text: <entity> 4.47 </entity> <entity type> monetaryItemType </entity type> <context> Non-U.S. net operating loss carryforwards of approximately $ 4.47 billion, of which $ 2.34 billion can be carried forward indefinitely, with the remaining $ 2.13 billion expiring in years 2025 through 2044. </context> | us-gaap:OperatingLossCarryforwards |
Non-U.S. net operating loss carryforwards of approximately $ 4.47 billion, of which $ 2.34 billion can be carried forward indefinitely, with the remaining $ 2.13 billion expiring in years 2025 through 2044. | text | 2.34 | monetaryItemType | text: <entity> 2.34 </entity> <entity type> monetaryItemType </entity type> <context> Non-U.S. net operating loss carryforwards of approximately $ 4.47 billion, of which $ 2.34 billion can be carried forward indefinitely, with the remaining $ 2.13 billion expiring in years 2025 through 2044. </context> | us-gaap:OperatingLossCarryforwards |
Non-U.S. net operating loss carryforwards of approximately $ 4.47 billion, of which $ 2.34 billion can be carried forward indefinitely, with the remaining $ 2.13 billion expiring in years 2025 through 2044. | text | 2.13 | monetaryItemType | text: <entity> 2.13 </entity> <entity type> monetaryItemType </entity type> <context> Non-U.S. net operating loss carryforwards of approximately $ 4.47 billion, of which $ 2.34 billion can be carried forward indefinitely, with the remaining $ 2.13 billion expiring in years 2025 through 2044. </context> | us-gaap:OperatingLossCarryforwards |
U.S. and foreign credit carryovers of $ 276.6 million, expiring in various amounts through 2044. | text | 276.6 | monetaryItemType | text: <entity> 276.6 </entity> <entity type> monetaryItemType </entity type> <context> U.S. and foreign credit carryovers of $ 276.6 million, expiring in various amounts through 2044. </context> | us-gaap:TaxCreditCarryforwardAmount |
Anticipatory foreign tax credits of $ 48.0 million which will generate from the reversal of future taxable income in certain non-U.S. jurisdictions which are taxed both in their local jurisdictions and in the U.S. | text | 48.0 | monetaryItemType | text: <entity> 48.0 </entity> <entity type> monetaryItemType </entity type> <context> Anticipatory foreign tax credits of $ 48.0 million which will generate from the reversal of future taxable income in certain non-U.S. jurisdictions which are taxed both in their local jurisdictions and in the U.S. </context> | us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign |
In India, the tax authorities have issued notices of assessments to the Company seeking unpaid taxes and interest for the financial years covering 2013 to 2018 concerning our tax position with respect to certain corporate tax deductions and certain intercompany transactions. Some of these issues were resolved through t... | text | 22.3 | monetaryItemType | text: <entity> 22.3 </entity> <entity type> monetaryItemType </entity type> <context> In India, the tax authorities have issued notices of assessments to the Company seeking unpaid taxes and interest for the financial years covering 2013 to 2018 concerning our tax position with respect to certain corporate tax deductio... | us-gaap:IncomeTaxExpenseBenefit |
In 2020, the Swedish Tax Authorities (“STA”) asserted an underpayment of tax against Meda A.B. for the tax years 2014 to 2019. The claim was that profits earned by its Luxembourg subsidiary should have been attributed to Meda A.B. The Company appealed the STA’s assessment to the Administrative Court of Stockholm. On Se... | text | 18.2 | monetaryItemType | text: <entity> 18.2 </entity> <entity type> monetaryItemType </entity type> <context> In 2020, the Swedish Tax Authorities (“STA”) asserted an underpayment of tax against Meda A.B. for the tax years 2014 to 2019. The claim was that profits earned by its Luxembourg subsidiary should have been attributed to Meda A.B. The... | us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss |
As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 would affect the Company’s effective tax rate if recognized, with the remainder being o... | text | 255.7 | monetaryItemType | text: <entity> 255.7 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 ... | us-gaap:UnrecognizedTaxBenefits |
As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 would affect the Company’s effective tax rate if recognized, with the remainder being o... | text | 272.8 | monetaryItemType | text: <entity> 272.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 ... | us-gaap:UnrecognizedTaxBenefits |
As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 would affect the Company’s effective tax rate if recognized, with the remainder being o... | text | 180.5 | monetaryItemType | text: <entity> 180.5 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 ... | us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate |
As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 would affect the Company’s effective tax rate if recognized, with the remainder being o... | text | 106.4 | monetaryItemType | text: <entity> 106.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 ... | us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued |
As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 would affect the Company’s effective tax rate if recognized, with the remainder being o... | text | 115.7 | monetaryItemType | text: <entity> 115.7 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 ... | us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued |
As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 would affect the Company’s effective tax rate if recognized, with the remainder being o... | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 wo... | us-gaap:IncomeTaxExaminationInterestExpense |
As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 would affect the Company’s effective tax rate if recognized, with the remainder being o... | text | 15.4 | monetaryItemType | text: <entity> 15.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 w... | us-gaap:IncomeTaxExaminationInterestExpense |
As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 would affect the Company’s effective tax rate if recognized, with the remainder being o... | text | 21.1 | monetaryItemType | text: <entity> 21.1 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $ 255.7 million and $ 272.8 million, respectively, of which $ 180.5 million as of December 31, 2024 w... | us-gaap:IncomeTaxExaminationInterestExpense |
The Company believes that it is reasonably possible that the amount of unrecognized tax benefits will decrease in the next twelve months by approximately $ 21.0 million, involving international and state audits and settlements and expiring statutes of limitations. The Company does not anticipate significant increases t... | text | 21.0 | monetaryItemType | text: <entity> 21.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company believes that it is reasonably possible that the amount of unrecognized tax benefits will decrease in the next twelve months by approximately $ 21.0 million, involving international and state audits and settlements and exp... | us-gaap:IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible |
, which had previously been approved by Mylan shareholders. The 2020 Incentive Plan includes 72,500,000 shares of Viatris’ common stock authorized for grant pursuant to the 2020 Incentive Plan, which may include dividend payments payable in common stock on unvested shares granted under awards. No shares remain availabl... | text | 72500000 | sharesItemType | text: <entity> 72500000 </entity> <entity type> sharesItemType </entity type> <context> , which had previously been approved by Mylan shareholders. The 2020 Incentive Plan includes 72,500,000 shares of Viatris’ common stock authorized for grant pursuant to the 2020 Incentive Plan, which may include dividend payments pa... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
, which had previously been approved by Mylan shareholders. The 2020 Incentive Plan includes 72,500,000 shares of Viatris’ common stock authorized for grant pursuant to the 2020 Incentive Plan, which may include dividend payments payable in common stock on unvested shares granted under awards. No shares remain availabl... | text | 49000000 | sharesItemType | text: <entity> 49000000 </entity> <entity type> sharesItemType </entity type> <context> , which had previously been approved by Mylan shareholders. The 2020 Incentive Plan includes 72,500,000 shares of Viatris’ common stock authorized for grant pursuant to the 2020 Incentive Plan, which may include dividend payments pa... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized |
As of December 31, 2024, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable each had average remaining contractual terms of 3.1 years. Also, at December 31, 2024, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had aggregate in... | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable each had average remaining contractual terms of 3.1 years. Also, at December 31, 2024, stock awards outstanding, s... | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested |
As of December 31, 2024, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable each had average remaining contractual terms of 3.1 years. Also, at December 31, 2024, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had aggregate in... | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable each had average remaining contractual terms of 3.1 years. Also, at December 31, 2024, stock awards outstanding, s... | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 |
Of the 13,859,002 Restricted Stock Awards granted during the year ended December 31, 2024, 9,592,720 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining Restricted Stock Awards granted, 12,920 are not subject to market conditions and will cliff vest within a thr... | text | 13859002 | sharesItemType | text: <entity> 13859002 </entity> <entity type> sharesItemType </entity type> <context> Of the 13,859,002 Restricted Stock Awards granted during the year ended December 31, 2024, 9,592,720 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining Restricted Stock Awar... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
Of the 13,859,002 Restricted Stock Awards granted during the year ended December 31, 2024, 9,592,720 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining Restricted Stock Awards granted, 12,920 are not subject to market conditions and will cliff vest within a thr... | text | 9592720 | sharesItemType | text: <entity> 9592720 </entity> <entity type> sharesItemType </entity type> <context> Of the 13,859,002 Restricted Stock Awards granted during the year ended December 31, 2024, 9,592,720 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining Restricted Stock Award... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
Of the 13,859,002 Restricted Stock Awards granted during the year ended December 31, 2024, 9,592,720 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining Restricted Stock Awards granted, 12,920 are not subject to market conditions and will cliff vest within a thr... | text | 12920 | sharesItemType | text: <entity> 12920 </entity> <entity type> sharesItemType </entity type> <context> Of the 13,859,002 Restricted Stock Awards granted during the year ended December 31, 2024, 9,592,720 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining Restricted Stock Awards ... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
Of the 13,859,002 Restricted Stock Awards granted during the year ended December 31, 2024, 9,592,720 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining Restricted Stock Awards granted, 12,920 are not subject to market conditions and will cliff vest within a thr... | text | 4253362 | sharesItemType | text: <entity> 4253362 </entity> <entity type> sharesItemType </entity type> <context> Of the 13,859,002 Restricted Stock Awards granted during the year ended December 31, 2024, 9,592,720 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining Restricted Stock Award... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
As of December 31, 2024, the Company had $ 163.4 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 1.4 years. The total intrinsic value of Restricted Stock Awards ... | text | 163.4 | monetaryItemType | text: <entity> 163.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had $ 163.4 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted ave... | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, but doe... | text | 1.29 | monetaryItemType | text: <entity> 1.29 </entity> <entity type> monetaryItemType </entity type> <context> The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuaria... | us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation |
The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, but doe... | text | 1.36 | monetaryItemType | text: <entity> 1.36 </entity> <entity type> monetaryItemType </entity type> <context> The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuaria... | us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation |
The weighted-average healthcare cost trend rate used for 2024 was 8.6 % declining to a projected 4.0 % in the year 2048. For 2025, the assumed weighted-average healthcare cost trend rate used will be 8.7 % declining to a projected 4.0 % in the year 2049. In selecting rates for current and long-term healthcare cost assu... | text | 8.6 | percentItemType | text: <entity> 8.6 </entity> <entity type> percentItemType </entity type> <context> The weighted-average healthcare cost trend rate used for 2024 was 8.6 % declining to a projected 4.0 % in the year 2048. For 2025, the assumed weighted-average healthcare cost trend rate used will be 8.7 % declining to a projected 4.0 %... | us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear |
The weighted-average healthcare cost trend rate used for 2024 was 8.6 % declining to a projected 4.0 % in the year 2048. For 2025, the assumed weighted-average healthcare cost trend rate used will be 8.7 % declining to a projected 4.0 % in the year 2049. In selecting rates for current and long-term healthcare cost assu... | text | 4.0 | percentItemType | text: <entity> 4.0 </entity> <entity type> percentItemType </entity type> <context> The weighted-average healthcare cost trend rate used for 2024 was 8.6 % declining to a projected 4.0 % in the year 2048. For 2025, the assumed weighted-average healthcare cost trend rate used will be 8.7 % declining to a projected 4.0 %... | us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1 |
The weighted-average healthcare cost trend rate used for 2024 was 8.6 % declining to a projected 4.0 % in the year 2048. For 2025, the assumed weighted-average healthcare cost trend rate used will be 8.7 % declining to a projected 4.0 % in the year 2049. In selecting rates for current and long-term healthcare cost assu... | text | 8.7 | percentItemType | text: <entity> 8.7 </entity> <entity type> percentItemType </entity type> <context> The weighted-average healthcare cost trend rate used for 2024 was 8.6 % declining to a projected 4.0 % in the year 2048. For 2025, the assumed weighted-average healthcare cost trend rate used will be 8.7 % declining to a projected 4.0 %... | us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear |
The Company maintains an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50 % of base salary and up to 100 % of bonus compensation, in each case, in addition to any amou... | text | 50 | percentItemType | text: <entity> 50 </entity> <entity type> percentItemType </entity type> <context> The Company maintains an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50 % of base ... | us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent |
The Company maintains an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50 % of base salary and up to 100 % of bonus compensation, in each case, in addition to any amou... | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> The Company maintains an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50 % of base... | us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent |
Total employer contributions to defined contribution plans were approximately $ 148.4 million, $ 129.3 million and $ 111.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 148.4 | monetaryItemType | text: <entity> 148.4 </entity> <entity type> monetaryItemType </entity type> <context> Total employer contributions to defined contribution plans were approximately $ 148.4 million, $ 129.3 million and $ 111.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:DefinedContributionPlanCostRecognized |
Total employer contributions to defined contribution plans were approximately $ 148.4 million, $ 129.3 million and $ 111.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 129.3 | monetaryItemType | text: <entity> 129.3 </entity> <entity type> monetaryItemType </entity type> <context> Total employer contributions to defined contribution plans were approximately $ 148.4 million, $ 129.3 million and $ 111.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:DefinedContributionPlanCostRecognized |
Total employer contributions to defined contribution plans were approximately $ 148.4 million, $ 129.3 million and $ 111.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 111.5 | monetaryItemType | text: <entity> 111.5 </entity> <entity type> monetaryItemType </entity type> <context> Total employer contributions to defined contribution plans were approximately $ 148.4 million, $ 129.3 million and $ 111.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:DefinedContributionPlanCostRecognized |
Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its large and diversified portfolio of branded and generic products, including complex products, to peop... | text | four | integerItemType | text: <entity> four </entity> <entity type> integerItemType </entity type> <context> Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its large and diver... | us-gaap:NumberOfReportableSegments |
Since the initiation of the 2020 restructuring program, the Company has incurred total pre-tax charges of approximately $ 1.4 billion through December 31, 2023. Such charges included approximately $ 450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including invent... | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> Since the initiation of the 2020 restructuring program, the Company has incurred total pre-tax charges of approximately $ 1.4 billion through December 31, 2023. Such charges included approximately $ 450 million of non-cash charges main... | us-gaap:RestructuringCharges |
Since the initiation of the 2020 restructuring program, the Company has incurred total pre-tax charges of approximately $ 1.4 billion through December 31, 2023. Such charges included approximately $ 450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including invent... | text | 450 | monetaryItemType | text: <entity> 450 </entity> <entity type> monetaryItemType </entity type> <context> Since the initiation of the 2020 restructuring program, the Company has incurred total pre-tax charges of approximately $ 1.4 billion through December 31, 2023. Such charges included approximately $ 450 million of non-cash charges main... | us-gaap:RestructuringReserveSettledWithoutCash2 |
Since the initiation of the 2020 restructuring program, the Company has incurred total pre-tax charges of approximately $ 1.4 billion through December 31, 2023. Such charges included approximately $ 450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including invent... | text | 950 | monetaryItemType | text: <entity> 950 </entity> <entity type> monetaryItemType </entity type> <context> Since the initiation of the 2020 restructuring program, the Company has incurred total pre-tax charges of approximately $ 1.4 billion through December 31, 2023. Such charges included approximately $ 450 million of non-cash charges main... | us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 |
For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $ 1.1 million, respectively. | text | 80.3 | monetaryItemType | text: <entity> 80.3 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $... | us-gaap:RestructuringCharges |
For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $ 1.1 million, respectively. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $ ... | us-gaap:RestructuringCharges |
For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $ 1.1 million, respectively. | text | 29.5 | monetaryItemType | text: <entity> 29.5 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $... | us-gaap:RestructuringCharges |
For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $ 1.1 million, respectively. | text | 13.9 | monetaryItemType | text: <entity> 13.9 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $... | us-gaap:RestructuringCharges |
For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $ 1.1 million, respectively. | text | 1.1 | monetaryItemType | text: <entity> 1.1 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2023, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 80.3 million, $ 0.4 million, $ 29.5 million, $ 13.9 million, and $ ... | us-gaap:RestructuringCharges |
For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.3 million, respectively. | text | 74.6 | monetaryItemType | text: <entity> 74.6 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.... | us-gaap:RestructuringCharges |
For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.3 million, respectively. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.3... | us-gaap:RestructuringCharges |
For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.3 million, respectively. | text | 0.9 | monetaryItemType | text: <entity> 0.9 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.3... | us-gaap:RestructuringCharges |
For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.3 million, respectively. | text | 8.2 | monetaryItemType | text: <entity> 8.2 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.3... | us-gaap:RestructuringCharges |
For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.3 million, respectively. | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2022, total restructuring charges in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $ 74.6 million, $ 2.5 million, $ 0.9 million, $ 8.2 million and $ 0.3... | us-gaap:RestructuringCharges |
In December 2023, the Company entered into a letter agreement, as amended, with Mapi for the development and commercialization of certain additional products, which is subject to finalization pending the execution of a definitive agreement. The Company made an initial upfront payment of $ 75.0 million which was account... | text | 75.0 | monetaryItemType | text: <entity> 75.0 </entity> <entity type> monetaryItemType </entity type> <context> In December 2023, the Company entered into a letter agreement, as amended, with Mapi for the development and commercialization of certain additional products, which is subject to finalization pending the execution of a definitive agre... | us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment |
. During the year ended December 31, 2023, the Company made an additional investment of $ 30.0 million in preferred shares of Mapi. The preferred shares are convertible on a one-to-one basis into Mapi ordinary shares at Viatris’ option. The Company recognized a gain of $ 45.6 million during the year ended December 31, ... | text | 30.0 | monetaryItemType | text: <entity> 30.0 </entity> <entity type> monetaryItemType </entity type> <context> . During the year ended December 31, 2023, the Company made an additional investment of $ 30.0 million in preferred shares of Mapi. The preferred shares are convertible on a one-to-one basis into Mapi ordinary shares at Viatris’ optio... | us-gaap:VariableInterestEntityFinancialOrOtherSupportAmount |
. During the year ended December 31, 2023, the Company made an additional investment of $ 30.0 million in preferred shares of Mapi. The preferred shares are convertible on a one-to-one basis into Mapi ordinary shares at Viatris’ option. The Company recognized a gain of $ 45.6 million during the year ended December 31, ... | text | 45.6 | monetaryItemType | text: <entity> 45.6 </entity> <entity type> monetaryItemType </entity type> <context> . During the year ended December 31, 2023, the Company made an additional investment of $ 30.0 million in preferred shares of Mapi. The preferred shares are convertible on a one-to-one basis into Mapi ordinary shares at Viatris’ optio... | us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss |
, $ 132.1 million related to our equity investments in Mapi, which included cumulative unrealized gains of $ 62.1 million, and within | text | 132.1 | monetaryItemType | text: <entity> 132.1 </entity> <entity type> monetaryItemType </entity type> <context> , $ 132.1 million related to our equity investments in Mapi, which included cumulative unrealized gains of $ 62.1 million, and within </context> | us-gaap:OtherAssets |
, $ 132.1 million related to our equity investments in Mapi, which included cumulative unrealized gains of $ 62.1 million, and within | text | 62.1 | monetaryItemType | text: <entity> 62.1 </entity> <entity type> monetaryItemType </entity type> <context> , $ 132.1 million related to our equity investments in Mapi, which included cumulative unrealized gains of $ 62.1 million, and within </context> | us-gaap:GainLossOnInvestments |
, $ 52.5 million related to advances, including for initial orders of commercial launch supply of GA Depot under our supply agreement with Mapi. Our maximum exposure to loss as a result of our involvement with Mapi is limited to the carrying value of the investments and advances. In 2024, the Company was informed that ... | text | 52.5 | monetaryItemType | text: <entity> 52.5 </entity> <entity type> monetaryItemType </entity type> <context> , $ 52.5 million related to advances, including for initial orders of commercial launch supply of GA Depot under our supply agreement with Mapi. Our maximum exposure to loss as a result of our involvement with Mapi is limited to the c... | us-gaap:PrepaidExpenseAndOtherAssetsCurrent |
, $ 52.5 million related to advances, including for initial orders of commercial launch supply of GA Depot under our supply agreement with Mapi. Our maximum exposure to loss as a result of our involvement with Mapi is limited to the carrying value of the investments and advances. In 2024, the Company was informed that ... | text | 184.6 | monetaryItemType | text: <entity> 184.6 </entity> <entity type> monetaryItemType </entity type> <context> , $ 52.5 million related to advances, including for initial orders of commercial launch supply of GA Depot under our supply agreement with Mapi. Our maximum exposure to loss as a result of our involvement with Mapi is limited to the ... | us-gaap:AssetImpairmentCharges |
Under the terms of the agreements, Theravance Biopharma is eligible to receive potential development and sales milestone payments totaling approximately $ 293 million in the aggregate. As of December 31, 2024, the Company has paid a total of $ 50.0 million in milestone payments to Theravance Biopharma. | text | 50.0 | monetaryItemType | text: <entity> 50.0 </entity> <entity type> monetaryItemType </entity type> <context> Under the terms of the agreements, Theravance Biopharma is eligible to receive potential development and sales milestone payments totaling approximately $ 293 million in the aggregate. As of December 31, 2024, the Company has paid a t... | us-gaap:ResearchAndDevelopmentExpense |
The Company has a total accrual of approximately $ 20.5 million related to these matters at December 31, 2024, which is included in other current liabilities in the consolidated balance sheets. Although it is reasonably possible that the Company may incur additional losses from these matters, any amount cannot be reaso... | text | 20.5 | monetaryItemType | text: <entity> 20.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company has a total accrual of approximately $ 20.5 million related to these matters at December 31, 2024, which is included in other current liabilities in the consolidated balance sheets. Although it is reasonably possible that ... | us-gaap:LitigationReserve |
The Company has accrued approximately $ 270 million in connection with the possible resolution of certain of these matters at December 31, 2024, which is included in other current liabilities in the consolidated balance sheets. Although it is reasonably possible that the Company may incur additional losses from these m... | text | 270 | monetaryItemType | text: <entity> 270 </entity> <entity type> monetaryItemType </entity type> <context> The Company has accrued approximately $ 270 million in connection with the possible resolution of certain of these matters at December 31, 2024, which is included in other current liabilities in the consolidated balance sheets. Althoug... | us-gaap:LossContingencyAccrualAtCarryingValue |
The Company has accrued approximately € 12.7 million as of December 31, 2024 related to this matter. It is reasonably possible that we will incur additional losses above the amount accrued but we cannot estimate a range of such reasonably possible losses at this time. There are no assurances, however, that settlements ... | text | 12.7 | monetaryItemType | text: <entity> 12.7 </entity> <entity type> monetaryItemType </entity type> <context> The Company has accrued approximately € 12.7 million as of December 31, 2024 related to this matter. It is reasonably possible that we will incur additional losses above the amount accrued but we cannot estimate a range of such reason... | us-gaap:LitigationReserve |
The Company has accrued approximately $ 70.1 million as of December 31, 2024 for its product liability matters. It is reasonably possible that we will incur additional losses and fees above the amount accrued but we cannot estimate a range of such reasonably possible losses or legal fees related to these claims at this... | text | 70.1 | monetaryItemType | text: <entity> 70.1 </entity> <entity type> monetaryItemType </entity type> <context> The Company has accrued approximately $ 70.1 million as of December 31, 2024 for its product liability matters. It is reasonably possible that we will incur additional losses and fees above the amount accrued but we cannot estimate a ... | us-gaap:LossContingencyAccrualAtCarryingValue |
The Company has approximately $ 2.9 million accrued related to its intellectual property matters at December 31, 2024. It is reasonably possible that we may incur additional losses and fees but we cannot estimate a range of such reasonably possible losses or legal fees related to these claims at this time. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company has approximately $ 2.9 million accrued related to its intellectual property matters at December 31, 2024. It is reasonably possible that we may incur additional losses and fees but we cannot estimate a range of such reason... | us-gaap:LossContingencyDamagesPaidValue |
The Company is involved in various other legal proceedings including commercial, contractual, employment, or other similar matters that are considered normal to its business. The Company has approximately $ 5.7 million accrued related to these various other legal proceedings at December 31, 2024. | text | 5.7 | monetaryItemType | text: <entity> 5.7 </entity> <entity type> monetaryItemType </entity type> <context> The Company is involved in various other legal proceedings including commercial, contractual, employment, or other similar matters that are considered normal to its business. The Company has approximately $ 5.7 million accrued related ... | us-gaap:LossContingencyAccrualAtCarryingValue |
Inventory costs include material, labor, and capitalized overhead. Inventories of $ 438.9 million and $ 465.5 million as of December 31, 2023 and 2022, respectively, were valued at the lower of cost or net realizable value using the last-in, first-out (“LIFO”) cost method. The remainder of inventory is valued at the ... | text | 438.9 | monetaryItemType | text: <entity> 438.9 </entity> <entity type> monetaryItemType </entity type> <context> Inventory costs include material, labor, and capitalized overhead. Inventories of $ 438.9 million and $ 465.5 million as of December 31, 2023 and 2022, respectively, were valued at the lower of cost or net realizable value using the... | us-gaap:LIFOInventoryAmount |
Inventory costs include material, labor, and capitalized overhead. Inventories of $ 438.9 million and $ 465.5 million as of December 31, 2023 and 2022, respectively, were valued at the lower of cost or net realizable value using the last-in, first-out (“LIFO”) cost method. The remainder of inventory is valued at the ... | text | 465.5 | monetaryItemType | text: <entity> 465.5 </entity> <entity type> monetaryItemType </entity type> <context> Inventory costs include material, labor, and capitalized overhead. Inventories of $ 438.9 million and $ 465.5 million as of December 31, 2023 and 2022, respectively, were valued at the lower of cost or net realizable value using the... | us-gaap:LIFOInventoryAmount |
We operate in two reportable business segments of the HVACR industry. Our segments are organized primarily by the nature of the products and services we provide. The following table describes each segment: | text | two | integerItemType | text: <entity> two </entity> <entity type> integerItemType </entity type> <context> We operate in two reportable business segments of the HVACR industry. Our segments are organized primarily by the nature of the products and services we provide. The following table describes each segment: </context> | us-gaap:NumberOfReportableSegments |
Prior to January 1, 2023, we operated in three reportable business segments. | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> Prior to January 1, 2023, we operated in three reportable business segments. </context> | us-gaap:NumberOfReportableSegments |
Previously, we operated in three reportable business segments. In November 2022, we announced the decision to explore strategic alternatives for our European portfolio and that we would continue to invest in our Heatcraft Worldwide Refrigeration business, all of which were previously in our Refrigeration segment. On J... | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> Previously, we operated in three reportable business segments. In November 2022, we announced the decision to explore strategic alternatives for our European portfolio and that we would continue to invest in our Heatcraft Worldwide Re... | us-gaap:NumberOfReportableSegments |
On March 1, 2019, we entered into an agreement with a financial institution to renew the lease of our corporate headquarters in Richardson, Texas for a term of five years through March 1, 2024 (the “Lake Park Renewal”). The leased property consists of an office building of approximately 192,000 square feet, land and re... | text | 41.2 | monetaryItemType | text: <entity> 41.2 </entity> <entity type> monetaryItemType </entity type> <context> On March 1, 2019, we entered into an agreement with a financial institution to renew the lease of our corporate headquarters in Richardson, Texas for a term of five years through March 1, 2024 (the “Lake Park Renewal”). The leased pro... | us-gaap:PaymentsToAcquireRealEstate |
Our Board of Directors have authorized a total of $ 4 billion to repurchase shares of our common stock (collectively referred to as the “Share Repurchase Plans”), including a $ 1.0 billion share repurchase authorization in July 2021. The Share Repurchase Plans allow us to repurchase shares from time to time in open mar... | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> Our Board of Directors have authorized a total of $ 4 billion to repurchase shares of our common stock (collectively referred to as the “Share Repurchase Plans”), including a $ 1.0 billion share repurchase authorization in July 2021. The... | us-gaap:StockRepurchaseProgramAuthorizedAmount1 |
Our Board of Directors have authorized a total of $ 4 billion to repurchase shares of our common stock (collectively referred to as the “Share Repurchase Plans”), including a $ 1.0 billion share repurchase authorization in July 2021. The Share Repurchase Plans allow us to repurchase shares from time to time in open mar... | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> Our Board of Directors have authorized a total of $ 4 billion to repurchase shares of our common stock (collectively referred to as the “Share Repurchase Plans”), including a $ 1.0 billion share repurchase authorization in July 2021. T... | us-gaap:StockRepurchaseProgramAuthorizedAmount1 |
Our Board of Directors have authorized a total of $ 4 billion to repurchase shares of our common stock (collectively referred to as the “Share Repurchase Plans”), including a $ 1.0 billion share repurchase authorization in July 2021. The Share Repurchase Plans allow us to repurchase shares from time to time in open mar... | text | 546 | monetaryItemType | text: <entity> 546 </entity> <entity type> monetaryItemType </entity type> <context> Our Board of Directors have authorized a total of $ 4 billion to repurchase shares of our common stock (collectively referred to as the “Share Repurchase Plans”), including a $ 1.0 billion share repurchase authorization in July 2021. T... | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
We used $ 300 million to purchase 1.3 million shares of our common stock in 2022 and $ 600 million to purchase 1.9 million shares of our common stock in 2021. No shares were repurchased in 2023. The shares repurchased are held as treasury shares. | text | 300 | monetaryItemType | text: <entity> 300 </entity> <entity type> monetaryItemType </entity type> <context> We used $ 300 million to purchase 1.3 million shares of our common stock in 2022 and $ 600 million to purchase 1.9 million shares of our common stock in 2021. No shares were repurchased in 2023. The shares repurchased are held as treas... | us-gaap:PaymentsForRepurchaseOfCommonStock |
We used $ 300 million to purchase 1.3 million shares of our common stock in 2022 and $ 600 million to purchase 1.9 million shares of our common stock in 2021. No shares were repurchased in 2023. The shares repurchased are held as treasury shares. | text | 1.3 | sharesItemType | text: <entity> 1.3 </entity> <entity type> sharesItemType </entity type> <context> We used $ 300 million to purchase 1.3 million shares of our common stock in 2022 and $ 600 million to purchase 1.9 million shares of our common stock in 2021. No shares were repurchased in 2023. The shares repurchased are held as treasur... | us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation |
We used $ 300 million to purchase 1.3 million shares of our common stock in 2022 and $ 600 million to purchase 1.9 million shares of our common stock in 2021. No shares were repurchased in 2023. The shares repurchased are held as treasury shares. | text | 600 | monetaryItemType | text: <entity> 600 </entity> <entity type> monetaryItemType </entity type> <context> We used $ 300 million to purchase 1.3 million shares of our common stock in 2022 and $ 600 million to purchase 1.9 million shares of our common stock in 2021. No shares were repurchased in 2023. The shares repurchased are held as treas... | us-gaap:PaymentsForRepurchaseOfCommonStock |
We used $ 300 million to purchase 1.3 million shares of our common stock in 2022 and $ 600 million to purchase 1.9 million shares of our common stock in 2021. No shares were repurchased in 2023. The shares repurchased are held as treasury shares. | text | 1.9 | sharesItemType | text: <entity> 1.9 </entity> <entity type> sharesItemType </entity type> <context> We used $ 300 million to purchase 1.3 million shares of our common stock in 2022 and $ 600 million to purchase 1.9 million shares of our common stock in 2021. No shares were repurchased in 2023. The shares repurchased are held as treasur... | us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation |
We recorded $ 3.1 million of restructuring charges in 2023 to reorganize or remove duplicative headcount and infrastructure. We recorded restructuring charges of $ 1.5 million in 2022 and $ 1.8 million in 2021 from activities initiated in prior years including the economic impact of COVID-19. There is not expected to b... | text | 3.1 | monetaryItemType | text: <entity> 3.1 </entity> <entity type> monetaryItemType </entity type> <context> We recorded $ 3.1 million of restructuring charges in 2023 to reorganize or remove duplicative headcount and infrastructure. We recorded restructuring charges of $ 1.5 million in 2022 and $ 1.8 million in 2021 from activities initiated... | us-gaap:RestructuringCharges |
We recorded $ 3.1 million of restructuring charges in 2023 to reorganize or remove duplicative headcount and infrastructure. We recorded restructuring charges of $ 1.5 million in 2022 and $ 1.8 million in 2021 from activities initiated in prior years including the economic impact of COVID-19. There is not expected to b... | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> We recorded $ 3.1 million of restructuring charges in 2023 to reorganize or remove duplicative headcount and infrastructure. We recorded restructuring charges of $ 1.5 million in 2022 and $ 1.8 million in 2021 from activities initiated... | us-gaap:RestructuringCharges |
We recorded $ 3.1 million of restructuring charges in 2023 to reorganize or remove duplicative headcount and infrastructure. We recorded restructuring charges of $ 1.5 million in 2022 and $ 1.8 million in 2021 from activities initiated in prior years including the economic impact of COVID-19. There is not expected to b... | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> We recorded $ 3.1 million of restructuring charges in 2023 to reorganize or remove duplicative headcount and infrastructure. We recorded restructuring charges of $ 1.5 million in 2022 and $ 1.8 million in 2021 from activities initiated... | us-gaap:RestructuringCharges |
of Lennox stores or to independent distributors. For the years ended December 31, 2023, 2022 and 2021, direct sales represented 75 %, 70 % and 73 % of revenues, respectively, and sales to independent distributors represented the remainder. Given the nature of our business, customer product orders are fulfilled at a poi... | text | 75 | monetaryItemType | text: <entity> 75 </entity> <entity type> monetaryItemType </entity type> <context> of Lennox stores or to independent distributors. For the years ended December 31, 2023, 2022 and 2021, direct sales represented 75 %, 70 % and 73 % of revenues, respectively, and sales to independent distributors represented the remaind... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
of Lennox stores or to independent distributors. For the years ended December 31, 2023, 2022 and 2021, direct sales represented 75 %, 70 % and 73 % of revenues, respectively, and sales to independent distributors represented the remainder. Given the nature of our business, customer product orders are fulfilled at a poi... | text | 70 | monetaryItemType | text: <entity> 70 </entity> <entity type> monetaryItemType </entity type> <context> of Lennox stores or to independent distributors. For the years ended December 31, 2023, 2022 and 2021, direct sales represented 75 %, 70 % and 73 % of revenues, respectively, and sales to independent distributors represented the remaind... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
of Lennox stores or to independent distributors. For the years ended December 31, 2023, 2022 and 2021, direct sales represented 75 %, 70 % and 73 % of revenues, respectively, and sales to independent distributors represented the remainder. Given the nature of our business, customer product orders are fulfilled at a poi... | text | 73 | monetaryItemType | text: <entity> 73 </entity> <entity type> monetaryItemType </entity type> <context> of Lennox stores or to independent distributors. For the years ended December 31, 2023, 2022 and 2021, direct sales represented 75 %, 70 % and 73 % of revenues, respectively, and sales to independent distributors represented the remaind... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
- In North America, we manufacture and sell unitary heating and cooling equipment used in light commercial applications, such as low-rise office buildings, restaurants, retail centers, churches and schools. These products are distributed primarily through commercial contractors and directly to national account custome... | text | 86 | percentItemType | text: <entity> 86 </entity> <entity type> percentItemType </entity type> <context> - In North America, we manufacture and sell unitary heating and cooling equipment used in light commercial applications, such as low-rise office buildings, restaurants, retail centers, churches and schools. These products are distribute... | us-gaap:ConcentrationRiskPercentage1 |
- In North America, we manufacture and sell unitary heating and cooling equipment used in light commercial applications, such as low-rise office buildings, restaurants, retail centers, churches and schools. These products are distributed primarily through commercial contractors and directly to national account custome... | text | 82 | percentItemType | text: <entity> 82 </entity> <entity type> percentItemType </entity type> <context> - In North America, we manufacture and sell unitary heating and cooling equipment used in light commercial applications, such as low-rise office buildings, restaurants, retail centers, churches and schools. These products are distribute... | us-gaap:ConcentrationRiskPercentage1 |
For the years ended December 31, 2023, 2022, and 2021 we recognized revenue of $ 7.7 million, $ 10.1 million and $ 3.6 million related to our contract liabilities at January 1, 2023, 2022 and 2021, respectively. Impairment losses recognized in our receivables and contract assets were de minimis in 2023, 2022 and 2021. | text | 7.7 | monetaryItemType | text: <entity> 7.7 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2023, 2022, and 2021 we recognized revenue of $ 7.7 million, $ 10.1 million and $ 3.6 million related to our contract liabilities at January 1, 2023, 2022 and 2021, respectively. Impairment losses reco... | us-gaap:ContractWithCustomerLiabilityRevenueRecognized |
For the years ended December 31, 2023, 2022, and 2021 we recognized revenue of $ 7.7 million, $ 10.1 million and $ 3.6 million related to our contract liabilities at January 1, 2023, 2022 and 2021, respectively. Impairment losses recognized in our receivables and contract assets were de minimis in 2023, 2022 and 2021. | text | 10.1 | monetaryItemType | text: <entity> 10.1 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2023, 2022, and 2021 we recognized revenue of $ 7.7 million, $ 10.1 million and $ 3.6 million related to our contract liabilities at January 1, 2023, 2022 and 2021, respectively. Impairment losses rec... | us-gaap:ContractWithCustomerLiabilityRevenueRecognized |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.